February 27th, 2018
Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.
December 14, 2018
The Foundation for the National Institutes of Health (FNIH) announces that the Accelerating Medicines Partnership (AMP) is extending the Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) & Related Autoimmune Disorders program to a sixth year. Additional financial support of $8.9 million from the public and private sectors will enable program researchers to deploy cutting-edge technologies to further analyze samples collected from clinical research volunteers living with RA or lupus.
March 19, 2018
Detailed molecular analyses of cells from rheumatoid arthritis (RA) synovium hold promise in identifying cellular phenotypes that drive tissue pathology and joint damage. The Accelerating Medicines Partnership (AMP) RA/SLE network aims to deconstruct autoimmune pathology by examining cells within target tissues through multiple high-dimensional assays. Robust standardized protocols need to be developed before cellular phenotypes at a single cell level can be effectively compared across patient samples
February 28, 2018
Researchers have identified three different synovial subtypes of rheumatoid arthritis that exhibit different mechanisms of pain and correlate with specific clinical phenotypes. The findings could be clinically meaningful and may help guide optimal treatment strategies for patients, as well as provide a better understanding of the cause of pain in patients with high tender and swollen joint counts but little tissue inflammation, according to the research team led by Dana E. Orange, MD, of the Hospital for Special Surgery and Rockefeller University in New York.
February 21, 2018
Datasets characterizing individual cells in rheumatoid arthritis and systemic lupus erythematosus disease tissue from the Accelerating Medicines Partnership for Rheumatoid Arthritis and Systemic Lupus Erythematosus(AMP RA/SLE) Phase I study are now available to the research community. Scientists from across the biomedical research community can access the AMP RA/SLE datasets to explore important research questions about these autoimmune conditions.
November 6, 2017
Scientists from Brigham and Women’s Hospital, speaking at the American College of Rheumatology/Association of Rheumatology Health Professionals annual conference in San Diego, say they relied on a new technique to analyze the cellular and molecular profiles of synovial tissue and peripheral blood to help develop more effective treatments for rheumatoid arthritis (RA).
November 6, 2017
In a recent research, a group of scientists have found a new and effective method to acquire viable cells from cryopreserved tissue samples, which could help researchers to collect and analyse samples from different study sites to conduct more centralized research. Rheumatoid arthritis (RA) is a chronic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints.
November 5, 2017
A newly developed tool to analyze the cellular and molecular profiles of synovial tissue and peripheral blood may help unlock clues about rheumatoid arthritis and lead to better therapies, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.
November 4, 2017
A new method for acquiring viable cells from cryopreserved tissue samples could provide researchers with a model for collecting and analyzing samples from different study sites to conduct more centralized research, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.
September 26, 2017
“Why do so many drugs fail in clinical trials?” asked Michael Brenner, MD, chief of rheumatology, immunology and allergy at Brigham and Women’s Hospital in Boston. This question, previously posed by Francis Collins, MD, PhD, director of the National Institutes of Health, prompted a discussion among scientists and stakeholders in the pharmaceutical industry. The conversation led to the foundation of the Accelerating Medicines Partnership (AMP) by the National Institutes of Health (NIH), pharmaceutical companies and nonprofit organizations.
February 04, 2014
Today, my Administration is taking action to accelerate the development of life-saving drugs and to help identify new treatments and cures for diseases like Alzheimer’s and diabetes. This new public-private partnership – the Accelerating Medicines Partnership – combines the considerable resources of America’s government with the innovation of our private sector companies in an effort to find new answers to today’s domestic and global public health challenges.
February 4, 2014
The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations today launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.